Search results | cephalon


Partnering Agreements with Cephalon

This report provides all the information you require to better understand Cephalon and its partnering interests and activities over the past seven years.


Cephalon: Company Profile

Cephalon, Inc. is an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd, is , is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Teva outbids Valeant to acquire Cephalon

Cephalon have accepted a bid from Teva which values the company at $6.8 billion, some $1.1 billion more than the Valeant offer of several weeks ago.

Cephalon snags Gemin X for lung cancer drug

Cephalon is once again on the acquisition trail

Cephalon license Mesenchymal precursor stem cell therapeutics for $2 billion

Cephalon, the largest biotechnology company in the regenerative medicine sector, have licensed Mesenchymal Precursor Stem Cell (MPC) therapeutics from Mesoblast for over $2 billion.

Cephalon acquires Mepha in deal valued at $615.4 million

Cephalon has once again demonstrated tremendous business acumen and expanded its range of pharmaceutical products and services within the developed and emerging markets with the acquisition of Mepha for $615.4 million.

Teva Pharmaceuticals

Teva Pharmaceuticals is a top pharmaceutical company based in Petach Tikva, Israel

Teva Pharmaceuticals M&A activity 2005-2013

Teva has announced 13 M&A deals since 2005, with the lead deals being the acquisitions of Cephalon, Ratiopharm and Barr Pharmaceuticals

Teva: Company profile

Teva Pharmaceuticals, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Top deal terminations of 2011

During 2011 there were eleven partnering deal terminations where the value of the original deal was in excess of $500 million

Teva looks set for a new round of M&A deals

Teva Pharmaceutical Industries aims to reduce its reliance on its key multiple sclerosis drug and expand in markets beyond the United States after a rise in profits due partly to growing sales of Copaxone.


Sorry, your search returned no results.


Acino to acquire Cephalon’s Middle East and North Africa business

Acino will acquire Cephalon’s combined Middle East and African business for a total consideration of approximately EUR 80 million.

Cephalon to pay Teva $275m if deal cancelled

Teva states in a notice to the US Securities and Exchange Commission (SEC) that if Cephalon cancels its acquisition by Teva, it will pay a fine of 4% of the $6.8 billion deal – or $275 million.

Acquisition agreement for Cephalon

Definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion

Fund sues Cephalon over Valeant bid

Valeant Pharmaceuticals may get some help in buying Cephalon from one of the company’s investors.

Cephalon to acquire Gemin X for $225m and up to $300m in milestones

Cephalon, Inc. has announced it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis.

Celator and Cephalon agree to extend research agreement into next phase of development

Celator Pharmaceuticals has announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development.

Cephalon, Inc. and Mesoblast Limited enter into strategic alliance to develop and commercialise novel therapeutic products for regenerative medicine

Cephalon, Inc. and Mesoblast Limited have announced they have entered into a strategic alliance to develop and commercialise novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

Cephalon to buy generic firm Mepha for $590 million

Cephalon will buy Mepha AG, the Swiss generic drugmaker owned by Germany’s Merckle family, for about $590 million (622.5 million Swiss francs) to diversify its product line and expand internationally.

Cephalon signs option agreement to acquire BioAssets Development

Cephalon will pay BDC an upfront payment of $30 million and, assuming exercise of the option, an additional payment on the closing of the acquisition. BDC stockholders could also receive additional future payments related to regulatory and sales milestones. The option agreement is subject to customary closing conditions including the receipt of necessary BDC stockholder more »

XOMA and Cephalon in antibody discovery deal

Collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite of integrated information and data management systems.